
|Articles|December 15, 2002
The Growth Factor
New York-The pharmacologic use of growth factors already FDA approved and useful in treating recalcitrant diabetic leg ulcers shows promise as an off-label therapy for other wounds that heal slowly, Chris Arpey, M.D., associate director of dermatologic surgery, University of Iowa, said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














